Dr Brander on Findings From the TRANSCEND CLL 004 Trial in Relapsed/Refractory CLL/SLL
Danielle M. Brander, MD, discusses the primary analysis of the phase 1/2 TRANSCEND CLL 004 trial in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Daniellem Brander Duke Health Duke Cancer Institute Hematologic Malignancies Cellular Therapy International Workshop On Cll
Source: onclive.com